Published in J Card Fail on August 21, 2009
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail (2011) 1.48
Plasma NGAL for the diagnosis of AKI in patients admitted from the emergency department setting. Clin J Am Soc Nephrol (2013) 1.31
Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail (2012) 1.10
Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol (2012) 1.08
Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol (2010) 1.05
Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization. Am Heart J (2011) 1.00
Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med (2012) 0.98
Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail (2011) 0.97
Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. Br J Pharmacol (2012) 0.95
Epidemiology and outcome of the cardio-renal syndrome. Heart Fail Rev (2011) 0.95
Neutrophil gelatinase-associated lipocalin: ready for routine clinical use? An international perspective. Blood Purif (2014) 0.94
Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol (2013) 0.92
Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure. J Card Fail (2013) 0.89
Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev (2014) 0.87
Biomarkers in acute heart failure--state of the art. Nat Rev Cardiol (2012) 0.87
Urinary Angiotensinogen Level Predicts AKI in Acute Decompensated Heart Failure: A Prospective, Two-Stage Study. J Am Soc Nephrol (2015) 0.86
Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol (2014) 0.86
Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care (2012) 0.86
Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail (2012) 0.84
Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc Disord (2012) 0.84
High serum and urine neutrophil gelatinase-associated lipocalin levels are independent predictors of renal progression in patients with immunoglobulin A nephropathy. Korean J Intern Med (2015) 0.84
Revisiting the cardio-renal hypothesis: the pivotal role of the kidney in congestive heart failure. Eur J Heart Fail (2011) 0.83
Heart-kidney interaction: epidemiology of cardiorenal syndromes. Int J Nephrol (2010) 0.82
Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use. PLoS One (2014) 0.82
Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev (2012) 0.81
Current and novel renal biomarkers in heart failure. Heart Fail Rev (2012) 0.81
Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome. Int J Nephrol (2011) 0.81
Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev (2014) 0.81
Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther (2012) 0.81
Acute heart failure: patient characteristics and pathophysiology. Curr Heart Fail Rep (2013) 0.80
Novel renal biomarkers to assess cardiorenal syndrome. Curr Heart Fail Rep (2014) 0.80
Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. PLoS One (2015) 0.79
Cardiorenal syndrome type 2: from diagnosis to optimal management. Ther Clin Risk Manag (2014) 0.79
Emerging biomarkers in heart failure and cardiac cachexia. Int J Mol Sci (2014) 0.78
Plasma neutrophil gelatinase-associated lipocalin: a marker of acute pyelonephritis in children. Pediatr Nephrol (2016) 0.78
Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study. PLoS One (2014) 0.78
Cardiorenal biomarkers in acute heart failure. J Geriatr Cardiol (2012) 0.78
Incorporating common biomarkers into the clinical management of heart failure. Curr Heart Fail Rep (2013) 0.78
Neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting. Exp Clin Cardiol (2013) 0.78
Renal dysfunction in acute heart failure. Korean Circ J (2011) 0.78
Comparison of serum creatinine and spot urine interleukin-18 levels following radiocontrast administration. Indian J Nephrol (2012) 0.77
Aqueous humor neutrophil gelatinase-associated lipocalin levels in patients with idiopathic acute anterior uveitis. Mol Vis (2010) 0.77
Biomarkers for the Early Detection and Prognosis of Acute Kidney Injury. Clin J Am Soc Nephrol (2016) 0.77
Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert Rev Cardiovasc Ther (2012) 0.76
Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function. Cardiorenal Med (2014) 0.76
Direct evidence of podocyte damage in cardiorenal syndrome type 2: preliminary evidence. Cardiorenal Med (2015) 0.76
Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations. Arq Bras Cardiol (2015) 0.76
Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. Eur Radiol (2010) 0.75
Development and Validation of a Risk Score for Prediction of Acute Kidney Injury in Patients With Acute Decompensated Heart Failure: A Prospective Cohort Study in China. J Am Heart Assoc (2016) 0.75
Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail (2013) 0.75
Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med (2017) 0.75
Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clin Res Cardiol (2015) 0.75
Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr Heart Fail Rep (2017) 0.75
The role of urine neutrophil gelatinase--associated lipocalin (NGAL) in acute heart failure in patients with ST--elevation myocardial infarction. BMC Cardiovasc Disord (2015) 0.75
Advances in the Management of Acute Cardiorenal Syndrome in China: Biomarkers for Predicting Development and Outcomes. Kidney Dis (Basel) (2016) 0.75
Decreased renal function in hypertensive emergencies. J Hum Hypertens (2014) 0.75
Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin on the First Day of Admission for Adverse Events in Patients With Acute Decompensated Heart Failure. J Am Heart Assoc (2017) 0.75
Evaluation of serum neutrophil gelatinase-associated lipocalin in predicting acute kidney injury in critically ill patients. J Int Med Res (2017) 0.75
The Number of GT(n) Repeats in the Hemeoxygenase-1 Gene Promoter is Increased in Pediatric Heart Failure but is Unrelated to Renal, Antioxidant and Anti-inflammatory Markers. Pediatr Cardiol (2015) 0.75
Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. Int J Mol Sci (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 13.77
Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol (2003) 9.08
Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med (2008) 5.89
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2009) 5.76
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol (2004) 4.14
Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology (2006) 3.66
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J (2004) 3.37
The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail (2002) 2.45
Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol (2006) 2.09
Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol (2006) 1.69
Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail (2008) 1.67
Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant (2008) 1.25
NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol (2007) 1.04
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2009) 5.76
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol (2012) 2.75
Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol (2008) 2.68
Spironolactone in chronic heart failure:all's well that ends well. J Am Coll Cardiol (2003) 2.47
Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol (2008) 2.47
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging (2009) 2.41
Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. Eur J Heart Fail (2012) 2.21
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J (2014) 2.08
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood (2011) 2.08
High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail (2010) 1.96
Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol (2008) 1.95
Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol (2008) 1.87
Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol (2009) 1.86
Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J (2008) 1.85
Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol (2009) 1.78
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol (2012) 1.69
Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol (2007) 1.66
Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol (2009) 1.64
Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol (2002) 1.63
The contributory role of gut microbiota in cardiovascular disease. J Clin Invest (2014) 1.57
Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm (2007) 1.57
Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet (2012) 1.54
Images in cardiovascular medicine. Tako-tsubo--like transient left ventricular dysfunction. Circulation (2003) 1.52
The impact of left ventricular size on response to cardiac resynchronization therapy. Am Heart J (2011) 1.45
Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart (2012) 1.45
Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol (2011) 1.44
Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol (2009) 1.44
Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease. Circulation (2012) 1.42
QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm (2012) 1.42
Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail (2013) 1.41
Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. Eur J Heart Fail (2014) 1.40
Dexamethasone, light anaesthesia, and tight glucose control (DeLiT) randomized controlled trial. Br J Anaesth (2013) 1.39
National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation (2007) 1.39
Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. J Am Coll Cardiol (2012) 1.37
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. Circulation (2010) 1.34
Cardiorenal syndrome in decompensated heart failure. Heart (2009) 1.34
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol (2013) 1.22
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest (2013) 1.21
Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study. Eur J Heart Fail (2011) 1.21
Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail (2013) 1.19
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18
Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail (2008) 1.18
Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res (2010) 1.18
Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation (2004) 1.17
Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J Am Coll Cardiol (2012) 1.15
Relationship among diastolic intraventricular pressure gradients, relaxation, and preload: impact of age and fitness. Am J Physiol Heart Circ Physiol (2005) 1.14
Right atrial volume index in chronic systolic heart failure and prognosis. JACC Cardiovasc Imaging (2009) 1.12
Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc (2013) 1.11
Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol (2013) 1.10
Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail (2012) 1.10
Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol (2013) 1.10
Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ Heart Fail (2010) 1.09
Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol (2008) 1.09
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol (2012) 1.08
Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog Cardiovasc Dis (2005) 1.07
Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ Heart Fail (2012) 1.06
Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol (2004) 1.06
Right ventricular response to intensive medical therapy in advanced decompensated heart failure. Circ Heart Fail (2010) 1.06
Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail (2009) 1.05
Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail (2013) 1.04
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail (2009) 1.04
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail (2012) 1.02
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation (2007) 1.00
Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. J Am Coll Cardiol (2010) 1.00
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail (2012) 1.00
Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. Circ Heart Fail (2015) 0.99
CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney. Hypertension (2012) 0.99